Free Trial
NYSE:MRK

Merck & Co., Inc. Q3 2025 Earnings Report

Merck & Co., Inc. logo
$89.44 -0.69 (-0.76%)
Closing price 10/2/2025 03:59 PM Eastern
Extended Trading
$89.38 -0.07 (-0.08%)
As of 10/2/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co., Inc. EPS Results

Actual EPS
N/A
Consensus EPS
$2.37
Beat/Miss
N/A
One Year Ago EPS
N/A

Merck & Co., Inc. Revenue Results

Actual Revenue
N/A
Expected Revenue
$17.00 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Merck & Co., Inc. Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, October 30, 2025
Conference Call Time
9:00AM ET

Conference Call Resources

Merck & Co., Inc. Earnings Headlines

The Tiny Stock Set to Soar with Musk's AI Ambitions
The Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires in history, one tiny AI stock is flying under the radar. While you can't invest directly, we've pinpointed a stock poised to benefit immensely from his plans.tc pixel
Merck (MRK) Shares Skyrocket, What You Need To Know
See More Merck & Co., Inc. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merck & Co., Inc.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merck & Co., Inc. and other key companies, straight to your email.

About Merck & Co., Inc.

Merck & Co., Inc. (NYSE:MRK) (NYSE: MRK) is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of a broad range of innovative human and animal health products. The company’s human health portfolio spans oncology, vaccines, infectious diseases, cardio-metabolic disorders and hospital acute care, with leading prescription medicines including Keytruda® for cancer immunotherapy, Gardasil® for HPV-related diseases and Januvia® for type 2 diabetes. In its animal health division, Merck provides vaccines and pharmaceutical therapies for livestock and companion animals, addressing conditions from parasitic infestations to respiratory and reproductive diseases.

Merck traces its origins to 1891 when George W. Merck established a U.S. affiliate of the German Merck company. The modern corporation took shape following World War I and has since grown through research breakthroughs and strategic acquisitions to become one of the world’s largest pharmaceutical companies. Its research and development efforts are supported by a global network of laboratories and manufacturing facilities, with major R&D centers in the United States, Europe and Asia.

Headquartered in Kenilworth, New Jersey, Merck operates in more than 140 countries, serving patients, healthcare professionals and animal health customers worldwide. The company maintains partnerships with academic institutions, government agencies and other biopharma organizations to advance scientific understanding and accelerate the delivery of novel therapies. Merck is committed to expanding access to its medicines and vaccines through pricing programs, licensing agreements and support for healthcare infrastructure in underserved regions.

Under the leadership of Chairman and Chief Executive Officer Robert M. Davis, Merck continues to invest in cutting-edge technologies such as mRNA platforms, cell and gene therapy, and next-generation oncology targets. The company’s mission is to translate innovative science into medicines and vaccines that help people and communities around the world.

View Merck & Co., Inc. Profile

More Earnings Resources from MarketBeat